一年一度的美國(guó)血液學(xué)会(ASH)年会是全球血液學(xué)领域规模最大、涵盖最全面的國(guó)际學(xué)术盛会之一。今年，第64届ASH年会将于12月10-13日在線(xiàn)下及線(xiàn)上召开，目前，万众瞩目的重磅研究Late-Breaking Abstracts(LBA)已经公布，其报告时间為(wèi)美國(guó)中部时间2022年12月13日上午9:00-10:30，让我们先盘点一下吧。

摘要号：LBA-1

英文(wén)标题：

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial.

中文(wén)标题：

贝林妥欧单抗巩固治疗可(kě)改善可(kě)测量残留病灶阴性缓解的新(xīn)诊断成人B-ALL患者的总體(tǐ)生存：来自ECOG-ACRIN E1910随机III期國(guó)家合作临床试验网络研究的结果。

报告人：

Mark R. Litzow

单位：

Division of Hematology, Mayo Clinic, Rochester, MN

摘要号：LBA-2

英文(wén)标题：

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study.

中文(wén)标题：

口服Iptacopan(一种B因子近端补體(tǐ)抑制剂)单药治疗阵发性睡眠性血红蛋白尿和残留性贫血患者的疗效优于静脉末端补體(tǐ)抑制治疗标准Eculizumab或Ravulizumab，且安全性良好：来自随机、主动对照、开放标签、多(duō)中心、III期Apply-PNH研究的结果。

报告人：

Regis Peffault De Latour

单位：

French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France

摘要号：LBA-3

英文(wén)标题：

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43).

中文(wén)标题：

与大剂量化疗联合自體(tǐ)造血干细胞移植(HDC-ASCT)作為(wèi)原发性中枢神经系统淋巴瘤患者巩固治疗相比，非清髓性化學(xué)免疫疗法对生存的影响——一项國(guó)际随机III期试验(MATRix/IELSG43)的结果。

报告人：

Gerald Illerhaus

单位：

Department of Hematology, Oncology Stem Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany

摘要号：LBA-4

英文(wén)标题：

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703.

中文(wén)标题：

移植后环磷酰胺、他(tā)克莫司和吗替麦考酚酯作為(wèi)减低强度预处理(lǐ)中预防移植物(wù)抗宿主病(GVHD)的新(xīn)标准:III期BMT CTN 1703研究的结果。

报告人：

Shernan G Holtan

单位：

University of Minnesota, Minneapolis, MN

摘要号：LBA-5

英文(wén)标题：

Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial.

中文(wén)标题：

低分(fēn)子肝素与标准妊娠治疗用(yòng)于复发性流产和遗传性血栓形成倾向女性的比较(ALIFE2):一项开放标签、III期随机对照试验。

报告人：

Saskia Middeldorp

单位：

Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

摘要号：LBA-6

英文(wén)标题：

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study.

中文(wén)标题：

在复发/难治性慢性淋巴细胞白血病和小(xiǎo)淋巴细胞淋巴瘤(R/R CLL/SLL)的治疗中，泽布替尼显示出优于伊布替尼的无进展生存期(PFS)：来自ALPINE随机III期研究的最终分(fēn)析结果。

报告人：

Jennifer R. Brown

单位：

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA